Adamas Pharmaceuticals (ADMS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Adamas Reports Second Quarter 2015 Financial Results
August 11, 2015 4:04 PM EDTEMERYVILLE, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the second quarter of 2015. The company reported a net loss attributable to common stockholders of $14.1 million, or $0.78 per share, for the quarter ended June 30, 2015. In the same period last year, the company reported net income attributable to common stockholders of $16.4 million, or $0.88 per share. Adamas ended the current quarter with $143.1 million in cash, cash equivalents, and available-for-sale securities compared to $158.7 million at December 31, 2014. This includes $8.5 million raised from the issuance of 472,141 shares of common stock through the quarter-end... More
